Figure 7.
Characterization of WR-Δ4 Virus Anti-tumor Features
(A) Scheme of the immunization protocol. C57BL/6 mice received 5 × 105 melanoma B16F10 cells/mouse (i.d.); when tumor volume reached 50 mm3, mice were treated (i.t.) with PBS or 1 × 108 PFU/mouse WR WT or WR-Δ4. Mice were sacrificed 4, 8, and 12 days after for characterization of viral replication, and innate and adaptive immune responses elicited. Tumor volume was measured daily. (B) Area under the curve was calculated considering the tumor volume of each mouse during the experiment. (C) Viral titer of homogenized tumors relative to tumor volume for each mouse. (D and E) The innate immune response is given as absolute numbers (relative to tumor volume for each mouse) of (D) neutrophils in tumor and (E) CD8 and CD4 T lymphocytes in spleen at 4, 8, and 12 days after treatment. Dashed lines indicate mean values for pretreated mice (day 0) in tumors or in spleen. (F and G) Adaptive immune response evaluated using ELISpot on splenocytes from mice at 12 days after stimulation with (F) B8R peptide and (G, left) gp100 and (G, right) TRP-2 peptides. Data are shown as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.005.